Tripeptidyl peptidase II is required for c-MYC-induced centriole overduplication and a novel therapeutic target in c-MYC-associated neoplasms

Genes and Cancer

Volumn 1, Issue 9, 2010, Pages 883-892

  Duensing, Stefan ^a,b   Darr, Sebastian ^a,c,d   Cuevas, Rolando ^a   Melquiot, Nadja ^c   Brickner, Anthony G ^a   Duensing, Anette ^a,b   Münger, Karl ^c  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Butabindide; c MYC; Cancer; Centrosome; TPPII

Indexed keywords

BUTABINDIDE; ENZYME INHIBITOR; MYC PROTEIN; PEPTIDASE; SMALL INTERFERING RNA; TRIPEPTIDYL PEPTIDASE II; TRIPEPTIDYL PEPTIDASE II INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BURKITT LYMPHOMA; CANCER INHIBITION; CENTRIOLE; CENTROSOME; CHROMOSOME ABERRATION; CONTROLLED STUDY; DRUG POTENCY; DRUG TARGETING; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LYMPHOMA CELL; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROTEIN LOCALIZATION;

EID: 79952846250     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601910389605     Document Type: Article

References (39)

1. Soucek L, Evan GI. The ups and downs of Myc biology. Curr Opin Genet Dev. 2010;20:91-5.
2. Mai S, Fluri M, Siwarski D, Huppi K. Genomic instability in MycERactivated Rat1A-MycER cells. Chromosome Res. 1996;4:365-71.
3. Felsher DW, Bishop JM. Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc Natl Acad Sci U S A.1999;96:3940-4.
4. Vafa O, Wade M, Kern S, et al. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell. 2002;9:1031-44.
5. Yin XY, Grove L, Datta NS, Long MW, Prochownik EV. C-myc overexpression and p53 loss cooperate to promote genomic instability. Oncogene. 1999;18:1177-84.
6. Korzeniewski N, Zheng L, Cuevas R, et al. Cullin 1 functions as a centrosomal suppressor of centriole multiplication by regulating pololike kinase 4 protein levels. Cancer Res. 2009;69:6668-75.
7. Duensing A, Spardy N, Chatterjee P, et al. Centrosome overduplication, chromosomal instability, and human papillomavirus oncoproteins. Environ Mol Mutagen. 2009;50:741-7.
8. Slack AD, Chen Z, Ludwig AD, Hicks J, Shohet JM. MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells. Cancer Res. 2007;67:2448-55.
9. Hasskarl J, Duensing S, Manuel E, Munger K. The helix-loop-helix protein ID1 localizes to centrosomes and rapidly induces abnormal centrosome numbers. Oncogene. 2004;23:1930-8.
10. Azimzadeh J, Bornens M. Structure and duplication of the centrosome. J Cell Sci. 2007;120:2139-42.
11. Nigg EA. Centrosome duplication: of rules and licenses. Trends Cell Biol. 2007;17:215-21.
12. Strnad P, Gonczy P. Mechanisms of procentriole formation. Trends Cell Biol. 2008;18:389-96.
13. Duensing A, Liu Y, Perdreau SA, Kleylein-Sohn J, Nigg EA, Duensing S. Centriole overduplication through the concurrent formation of multiple daughter centrioles at single maternal templates. Oncogene.2007;26:6280-8.
14. Strnad P, Leidel S, Vinogradova T, Euteneuer U, Khodjakov A, Gonczy P. Regulated HsSAS-6 levels ensure formation of a single procentriole per centriole during the centrosome duplication cycle. Dev Cell.2007;13:203-13.
15. Habedanck R, Stierhof YD, Wilkinson CJ, Nigg EA. The Polo kinase Plk4 functions in centriole duplication. Nat Cell Biol. 2005;7:1140-6.
16. Kleylein-Sohn J, Westendorf J, Le Clech M, Habedanck R, Stierhof YD, Nigg EA. Plk4-induced centriole biogenesis in human cells. Dev Cell. 2007;13:190-202.
17. Bettencourt-Dias M, Rodrigues-Martins A, Carpenter L, et al. SAK/ PLK4 is required for centriole duplication and flagella development. Curr Biol. 2005;15:2199-207.
18. Cunha-Ferreira I, Rodrigues-Martins A, Bento I, et al. The SCF/Slimb ubiquitin ligase limits centrosome amplification through degradation of SAK/PLK4. Curr Biol. 2009;19:43-9.
19. Fabunmi RP, Wigley WC, Thomas PJ, DeMartino GN. Activity and regulation of the centrosome-associated proteasome. J Biol Chem.2000;275:409-13.
20. Wigley WC, Fabunmi RP, Lee MG, et al. Dynamic association of proteasomal machinery with the centrosome. J Cell Biol. 1999;145:481-90.
21. Tsou MF, Stearns T. Mechanism limiting centrosome duplication to once per cell cycle. Nature. 2006;442:947-51.
22. Hung CF, Cheng WF, He L, et al. Enhancing major histocompatibility complex class I antigen presentation by targeting antigen to centrosomes. Cancer Res. 2003;63:2393-8.
23. Kawahara M, York IA, Hearn A, Farfan D, Rock KL. Analysis of the role of tripeptidyl peptidase II in MHC class I antigen presentation in vivo. J Immunol. 2009;183:6069-77.
24. Guil S, Rodriguez-Castro M, Aguilar F, Villasevil EM, Anton LC, Del Val M. Need for tripeptidyl-peptidase II in major histocompatibility complex class I viral antigen processing when proteasomes are detrimental. J Biol Chem. 2006;281:39925-34.
25. York IA, Bhutani N, Zendzian S, Goldberg AL, Rock KL. Tripeptidyl peptidase II is the major peptidase needed to trim long antigenic precursors, but is not required for most MHC class I antigen presentation. J Immunol. 2006;177:1434-43.
26. Chuang CK, Rockel B, Seyit G, et al. Hybrid molecular structure of the giant protease tripeptidyl peptidase II. Nat Struct Mol Biol.2010;17:990-6.
27. Gavioli R, Frisan T, Vertuani S, Bornkamm GW, Masucci MG. c-myc overexpression activates alternative pathways for intracellular proteolysis in lymphoma cells. Nat Cell Biol. 2001;3:283-8.
28. Duensing S, Lee BH, Dal Cin P, Munger K. Excessive centrosome abnormalities without ongoing numerical chromosome instability in a Burkitt's lymphoma. Mol Cancer. 2003;2:30.
29. Rose C, Vargas F, Facchinetti P, et al. Characterization and inhibition of a cholecystokinin-inactivating serine peptidase. Nature.1996;380:403-9.
30. Geier E, Pfeifer G, Wilm M, et al. A giant protease with potential to substitute for some functions of the proteasome. Science.1999;283:978-81.
31. Glas R, Bogyo M, McMaster JS, Gaczynska M, Ploegh HL. A proteolytic system that compensates for loss of proteasome function. Nature.1998;392:618-22.
32. Stavropoulou V, Xie J, Henriksson M, Tomkinson B, Imreh S, Masucci MG. Mitotic infidelity and centrosome duplication errors in cells overexpressing tripeptidyl-peptidase II. Cancer Res. 2005;65:1361-8.
33. Wang EW, Kessler BM, Borodovsky A, et al. Integration of the ubiquitin-proteasome pathway with a cytosolic oligopeptidase activity. Proc Natl Acad Sci U S A. 2000;97:9990-5.
34. Rapoport AP, Simons-Evelyn M, Chen T, et al. Flavopiridol induces apoptosis and caspase-3 activation of a newly characterized Burkitt's lymphoma cell line containing mutant p53 genes. Blood Cells Mol Dis. 2001;27:610-24.
35. Princiotta MF, Schubert U, Chen W, et al. Cells adapted to the proteasome inhibitor 4-hydroxy-5-iodo-3-nitrophenylacetyl-Leu- Leu-leucinal-vinyl sulfone require enzymatically active proteasomes for continued survival. Proc Natl Acad Sci U S A. 2001;98:513-8.
36. Gasteiger E, Hoogland C, Gattiker A, et al. Protein identification and analysis tools on the ExPASy server. Totowa, NJ: Humana Press; 2005.
37. Piel M, Meyer P, Khodjakov A, Rieder CL, Bornens M. The respective contributions of the mother and daughter centrioles to centrosome activity and behavior in vertebrate cells. J Cell Biol. 2000;149:317-30.
38. Duensing S, Münger K. The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability. Cancer Res. 2002;62:7075-82.
39. Duensing S, Lee LY, Duensing A, et al. The human papillomavirus type 16 E6 and E7 oncoproteins cooperate to induce mitotic defects and genomic instability by uncoupling centrosome duplication from the cell division cycle. Proc Natl Acad Sci U S A. 2000;97:10002-7.